A Triple-blinded, Randomised, Placebo-controlled Trial to Examine the Efficacy and Safety of ViNeuro in Patients With Parkinson's Disease

Inclusion criteria

• A subject will be eligible for study participation if he/she meets all the following criteria:

• Age of at least 30 years
• Diagnosis of symptomatic, idiopathic Parkinson' disease using The United Kingdom Parkinson's Disease Society Brain Bank Diagnostic Criteria (Appendix 3 in the protocol)
• Stage 1-4 on the modified Hoehn and Yahr scale (Appendix 4 in the protocol)
• Possesses three of the four cardinal signs of Parkinson's disease, i.e. rigidity, bradykinesia, resting tremor and postural instability, without any other known or suspected cause for their parkinsonism
• If receiving levodopa or other symptomatic treatments, the subject should have shown a good response to it and have been on a stable dosage for at least 1 month prior to study entry
• Voluntarily signs and dates an Informed Consent Form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), prior to any study-specific procedures.

Exclusion criteria

• A subject will be excluded from the study if he/she meets any of the following criteria:

• Presence of atypical parkinsonian syndromes
• Dementia as defined by the Mini-Mental State Examination score (Appendix 5 in the protocol) of 22 or less
• Serious concurrent illness, such as active cardiac, renal, liver, or neoplastic disease
• Used centrally active therapies, e.g. hypnotics, antidepressants, anxiolytics, within 60 days before study entry
• Used methylphenidate, cinnarizine, reserpine, amphetamine, or monoamine oxidase-A inhibitors, e.g. pargyline, phenelzine, or tranylcpromine, within 3 months of study entry
• Has history of receiving any neuroleptics
• Used alpha-methyldopa or flunarizine within 6 months of study entry
• Females who are pregnant or breastfeeding.
• Subjects who are currently participating in another investigational study or has been taking any investigational drug within the last 4 weeks prior to screening of this study (Visit 1).
• Subjects who are taking any traditional Chinese medication, or has been taking any traditional Chinese medication within the last 2 weeks prior to screening of this study (Visit 1).
• Any criteria, which, in the opinion of the investigator, suggests that the subject would not be compliant with the study protocol.